| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 17 | 2023 | 258 | 6.800 |
Why?
|
| Hepatitis B virus | 13 | 2023 | 217 | 4.600 |
Why?
|
| Hepatitis B, Chronic | 11 | 2022 | 137 | 4.260 |
Why?
|
| Virus Activation | 11 | 2022 | 228 | 3.120 |
Why?
|
| Hepatitis C | 6 | 2022 | 524 | 2.060 |
Why?
|
| Antiviral Agents | 12 | 2022 | 1230 | 2.000 |
Why?
|
| Neoplasms | 27 | 2023 | 15193 | 1.840 |
Why?
|
| Mass Screening | 17 | 2023 | 1509 | 1.730 |
Why?
|
| Hepacivirus | 6 | 2022 | 397 | 1.370 |
Why?
|
| HIV Infections | 5 | 2023 | 2134 | 1.130 |
Why?
|
| Hepatitis C, Chronic | 5 | 2021 | 451 | 1.060 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 171 | 1.060 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2020 | 27 | 0.970 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 1209 | 0.900 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 6550 | 0.900 |
Why?
|
| Antineoplastic Agents | 10 | 2022 | 14289 | 0.850 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 7 | 2024 | 421 | 0.850 |
Why?
|
| Hepatitis C Antibodies | 2 | 2020 | 41 | 0.820 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 1375 | 0.730 |
Why?
|
| Hepatitis B Surface Antigens | 6 | 2023 | 84 | 0.700 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2021 | 1833 | 0.690 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 1258 | 0.660 |
Why?
|
| Rituximab | 3 | 2021 | 1528 | 0.640 |
Why?
|
| Immunization, Passive | 1 | 2018 | 172 | 0.630 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 180 | 0.610 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 1039 | 0.570 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 698 | 0.570 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2019 | 2027 | 0.550 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1870 | 0.540 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 1320 | 0.540 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1350 | 0.530 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 4557 | 0.520 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 980 | 0.480 |
Why?
|
| Humans | 63 | 2024 | 261506 | 0.470 |
Why?
|
| Adult | 30 | 2022 | 77950 | 0.450 |
Why?
|
| Aged | 26 | 2021 | 70117 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 864 | 0.420 |
Why?
|
| Middle Aged | 28 | 2021 | 86204 | 0.410 |
Why?
|
| Mothers | 2 | 2018 | 410 | 0.410 |
Why?
|
| Resuscitation Orders | 3 | 2009 | 68 | 0.400 |
Why?
|
| Cancer Care Facilities | 2 | 2013 | 884 | 0.390 |
Why?
|
| Acculturation | 4 | 2013 | 112 | 0.380 |
Why?
|
| Qualitative Research | 5 | 2024 | 556 | 0.380 |
Why?
|
| Prevalence | 8 | 2022 | 3260 | 0.370 |
Why?
|
| Vaginal Smears | 2 | 2021 | 192 | 0.370 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 244 | 0.370 |
Why?
|
| Risk Factors | 9 | 2023 | 17523 | 0.360 |
Why?
|
| Hepatitis B Vaccines | 2 | 2018 | 51 | 0.350 |
Why?
|
| Liver Cirrhosis | 4 | 2021 | 941 | 0.340 |
Why?
|
| Female | 34 | 2024 | 141928 | 0.340 |
Why?
|
| Attitude to Health | 1 | 2012 | 465 | 0.340 |
Why?
|
| Young Adult | 12 | 2020 | 21445 | 0.330 |
Why?
|
| Vietnam | 4 | 2013 | 56 | 0.330 |
Why?
|
| Patient Care | 1 | 2010 | 149 | 0.330 |
Why?
|
| Community Health Services | 1 | 2010 | 126 | 0.330 |
Why?
|
| Hepatitis B Antibodies | 4 | 2023 | 58 | 0.330 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2390 | 0.320 |
Why?
|
| Adolescent | 13 | 2021 | 31252 | 0.320 |
Why?
|
| Hepatitis | 1 | 2009 | 93 | 0.320 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2009 | 89 | 0.310 |
Why?
|
| Male | 27 | 2021 | 123000 | 0.300 |
Why?
|
| Liver Failure | 2 | 2019 | 140 | 0.300 |
Why?
|
| Documentation | 2 | 2008 | 207 | 0.290 |
Why?
|
| Focus Groups | 3 | 2012 | 256 | 0.290 |
Why?
|
| Universities | 1 | 2008 | 160 | 0.290 |
Why?
|
| Survivors | 1 | 2012 | 1031 | 0.280 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2009 | 318 | 0.270 |
Why?
|
| Recurrence | 3 | 2021 | 4758 | 0.260 |
Why?
|
| Students | 1 | 2008 | 324 | 0.260 |
Why?
|
| Emergency Service, Hospital | 2 | 2009 | 1148 | 0.260 |
Why?
|
| Incidence | 4 | 2021 | 5673 | 0.250 |
Why?
|
| Health Personnel | 1 | 2010 | 625 | 0.240 |
Why?
|
| Referral and Consultation | 1 | 2010 | 899 | 0.240 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 2843 | 0.230 |
Why?
|
| Retrospective Studies | 11 | 2022 | 37905 | 0.230 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 918 | 0.220 |
Why?
|
| Interprofessional Relations | 1 | 2004 | 213 | 0.220 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 98 | 0.220 |
Why?
|
| Alanine Transaminase | 2 | 2021 | 227 | 0.210 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 4314 | 0.210 |
Why?
|
| Texas | 6 | 2013 | 6311 | 0.200 |
Why?
|
| United States | 8 | 2023 | 15433 | 0.200 |
Why?
|
| Papillomaviridae | 2 | 2022 | 624 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.190 |
Why?
|
| Guanine | 1 | 2021 | 151 | 0.190 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 141 | 0.190 |
Why?
|
| Liver Transplantation | 1 | 2009 | 1112 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2020 | 75 | 0.180 |
Why?
|
| Emergency Medical Services | 1 | 2004 | 429 | 0.180 |
Why?
|
| Quality of Life | 3 | 2021 | 4532 | 0.180 |
Why?
|
| Advisory Committees | 1 | 2020 | 203 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 223 | 0.170 |
Why?
|
| RNA, Viral | 2 | 2020 | 671 | 0.170 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 219 | 0.170 |
Why?
|
| Decision Trees | 1 | 2019 | 178 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 15862 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2020 | 329 | 0.160 |
Why?
|
| Life Style | 1 | 2022 | 612 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 226 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 1217 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5542 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 9244 | 0.140 |
Why?
|
| Medicare | 1 | 2021 | 860 | 0.140 |
Why?
|
| Adenine | 1 | 2019 | 631 | 0.140 |
Why?
|
| Glucokinase | 1 | 2016 | 21 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 1021 | 0.140 |
Why?
|
| Leukemia | 1 | 2004 | 1635 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2017 | 495 | 0.140 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.130 |
Why?
|
| Age Distribution | 1 | 2017 | 698 | 0.130 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.130 |
Why?
|
| Nutrition Surveys | 3 | 2022 | 295 | 0.130 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 32 | 0.130 |
Why?
|
| Hepatitis B Antigens | 2 | 2015 | 15 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 945 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 2403 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2019 | 785 | 0.120 |
Why?
|
| Graft vs Host Disease | 2 | 2018 | 2638 | 0.120 |
Why?
|
| Piperidines | 1 | 2019 | 1035 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 29902 | 0.120 |
Why?
|
| Rheumatic Diseases | 1 | 2013 | 54 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1360 | 0.110 |
Why?
|
| Methylphenidate | 1 | 2014 | 103 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 1914 | 0.110 |
Why?
|
| Mother-Child Relations | 1 | 2013 | 81 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2018 | 769 | 0.110 |
Why?
|
| Intention | 1 | 2013 | 109 | 0.110 |
Why?
|
| Korea | 1 | 2012 | 63 | 0.110 |
Why?
|
| Grounded Theory | 1 | 2012 | 6 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 735 | 0.110 |
Why?
|
| Decision Making | 2 | 2019 | 1287 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 851 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 929 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2016 | 398 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2021 | 6100 | 0.100 |
Why?
|
| Disease Progression | 3 | 2018 | 6682 | 0.100 |
Why?
|
| China | 1 | 2012 | 606 | 0.100 |
Why?
|
| Sex Factors | 2 | 2008 | 2139 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 195 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2012 | 497 | 0.090 |
Why?
|
| Liver | 2 | 2018 | 2961 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 2352 | 0.090 |
Why?
|
| Data Collection | 2 | 2011 | 620 | 0.090 |
Why?
|
| Body Image | 1 | 2011 | 141 | 0.090 |
Why?
|
| Medical Oncology | 2 | 2019 | 1423 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 586 | 0.090 |
Why?
|
| Cultural Characteristics | 1 | 2010 | 70 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2012 | 694 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4367 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1362 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2009 | 57 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2013 | 834 | 0.080 |
Why?
|
| Survival | 1 | 2009 | 177 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 589 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2015 | 1335 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 860 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 573 | 0.080 |
Why?
|
| Research Design | 1 | 2016 | 1544 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 4988 | 0.080 |
Why?
|
| Fibrosis | 2 | 2022 | 793 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.080 |
Why?
|
| Advance Care Planning | 1 | 2009 | 86 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 152 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 211 | 0.080 |
Why?
|
| alpha-Fetoproteins | 1 | 2009 | 237 | 0.080 |
Why?
|
| Fatigue | 1 | 2014 | 1239 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 1293 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 830 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 3976 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 1130 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2014 | 1589 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 5437 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 9180 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2195 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 598 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2004 | 102 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1443 | 0.060 |
Why?
|
| Benchmarking | 1 | 2005 | 273 | 0.060 |
Why?
|
| Child | 4 | 2018 | 29154 | 0.060 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2004 | 250 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2023 | 355 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 462 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2004 | 330 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 54 | 0.050 |
Why?
|
| Social Support | 1 | 2024 | 560 | 0.050 |
Why?
|
| Poverty | 1 | 2024 | 471 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1225 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 256 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2004 | 358 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 5687 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2021 | 253 | 0.040 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 171 | 0.040 |
Why?
|
| Prognosis | 2 | 2009 | 21713 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 690 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3578 | 0.040 |
Why?
|
| Age Factors | 1 | 2008 | 5377 | 0.040 |
Why?
|
| Adipokines | 1 | 2018 | 96 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2014 | 8223 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2019 | 32848 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2018 | 234 | 0.040 |
Why?
|
| Selection Bias | 1 | 2016 | 50 | 0.040 |
Why?
|
| Survival Rate | 1 | 2009 | 12221 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2018 | 448 | 0.030 |
Why?
|
| Sulfonylurea Receptors | 1 | 2014 | 22 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 381 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 177 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 13310 | 0.030 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2014 | 42 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 627 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 1183 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1440 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 1866 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 208 | 0.030 |
Why?
|
| Global Health | 1 | 2018 | 657 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2578 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 437 | 0.030 |
Why?
|
| Genotype | 1 | 2021 | 4109 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2018 | 731 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 4971 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 460 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 225 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 3441 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 11538 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 59536 | 0.020 |
Why?
|
| Smoking | 1 | 2019 | 2440 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 15694 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 133 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2004 | 16273 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2588 | 0.020 |
Why?
|
| Terminally Ill | 1 | 2008 | 91 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 2422 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4744 | 0.020 |
Why?
|
| Obesity | 1 | 2019 | 2884 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 14889 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 7222 | 0.010 |
Why?
|
| Palliative Care | 1 | 2008 | 2037 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 11965 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 34495 | 0.010 |
Why?
|